2022年12月26日 · We describe the real-world outcomes of photodynamic therapy (PDT) for chronic central serous chorioretinopathy (CSCR) in a single centre over nine years. We carried out a retrospective...

In comparing the anatomic and functional efficacy and safety of PDT vs SML in treating CSCR, there are mixed results. A study comparing 577 nm SML with PDT in the treatment of chronic CSCR showed a better treatment response in the SML group and greater improvement in central retinal thickness in the SML group.

There is sufficient scientific evidence to suggest that PDT may be a useful treatment option for chronic CSCR in the short-term. The review identifies a need for robust RCTs with longer follow-up to ascertain the role of PDT as a useful treatment option for CSCR.

Data on indications for PDT in CSCR, dosing regimens of verteprofin PDT (which includes treatment dose of vertoporfin, treatment time, fluence, and spot size), number of treatment sessions, response to treatment, mean length of follow-up, …

One level I study showed that photodynamic therapy (PDT) using half-dose verteporfin for acute CSCR led to a significant decrease in subretinal fluid (SRF) with 95% of treated patients having no SRF at 12 months compared with 58% of untreated eyes with acute CSCR (P = 0.001).

Central Serous Chorioretinopathy. Central serous chorioretinopathy (CSCR) is characterized by metamorphopsia and loss of central vision due to the accumulation of subretinal fluid (SRF) in the macula. This is secondary to hyperpermeability, thickening …

2014年6月20日 · Data on indications for PDT in CSCR, dosing regimens of verteprofin PDT (which includes treatment dose of vertoporfin, treatment time, fluence, and spot size), number of treatment sessions,...

2023年5月11日 · In this randomized, controlled trial, we compared SMLT using 577-nm yellow laser with half-dose PDT for treating patients with chronic CSCR. We found that half-dose PDT achieved complete resolution of SRF faster than SMLT.

We suggest that if CSCR is not spontaneously improving over 3 months the patient should be offered PDT, to prevent VA loss from the long-term presence of subretinal fluid in the macula. PDT is not associated with loss of vision in eyes with chronic CSCR, and can be safely used in eyes with relativel …

We describe the real-world outcomes of photodynamic therapy (PDT) for chronic central serous chorioretinopathy (CSCR) in a single centre over nine years. We carried out a retrospective analysis of patients with chronic CSCR who received half dose PDT in a …